MY138975A - Novel preparation and administration form comprising an acid-labile active compound - Google Patents
Novel preparation and administration form comprising an acid-labile active compoundInfo
- Publication number
- MY138975A MY138975A MYPI20002403A MYPI20002403A MY138975A MY 138975 A MY138975 A MY 138975A MY PI20002403 A MYPI20002403 A MY PI20002403A MY PI20002403 A MYPI20002403 A MY PI20002403A MY 138975 A MY138975 A MY 138975A
- Authority
- MY
- Malaysia
- Prior art keywords
- active compound
- acid
- administration form
- mixture
- labile active
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
NOVEL ADMINISTRATION FORMS AND PREPARATIONS FOR ACID-LABILE ACTIVE COMPOUNDS ARE DESCRIBED. THE NOVEL ADMINISTRATION FORMS CONTAIN INDIVIDUAL ACTIVE COMPOUND UNITS, THE ACTIVE COMPOUND BEING PRESENT IN THE ACTIVE COMPOUND UNITS IN A MATRIX MADE OF A MIXTURE COMPRISING AT LEAST ONE FATTY ALCOHOL AND AT LEAST ONE SOLID PARAFIN, IN A MATRIX MADE OF A MIXTURE OF A TRIGLYCERIDE AND AT LEAST ONE SOLID PARAFFIN OR IN A MATRIX MADE OF A MIXTURE COMPRISING AT LEAST ONE FATTY ACID ESTER AND AT LEAST ONE SOLID PARAFFIN. IN PARTICULAR, THE ACTIVE COMPOUND UNITS ARE MICROSPHERES WHICH CAN BE PRODUCED BY PRILLING.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19925710A DE19925710C2 (en) | 1999-06-07 | 1999-06-07 | New preparation and dosage form containing an acid labile proton pump inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
MY138975A true MY138975A (en) | 2009-08-28 |
Family
ID=7910295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI20002403A MY138975A (en) | 1999-06-07 | 2000-05-30 | Novel preparation and administration form comprising an acid-labile active compound |
Country Status (6)
Country | Link |
---|---|
AR (1) | AR024310A1 (en) |
CO (1) | CO5160296A1 (en) |
DE (1) | DE19925710C2 (en) |
MY (1) | MY138975A (en) |
PE (1) | PE20010303A1 (en) |
TW (1) | TWI255720B (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA80393C2 (en) | 2000-12-07 | 2007-09-25 | Алтана Фарма Аг | Pharmaceutical preparation comprising an pde inhibitor dispersed on a matrix |
PT1341524E (en) * | 2000-12-07 | 2011-12-30 | Nycomed Gmbh | Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient |
US7357943B2 (en) | 2000-12-07 | 2008-04-15 | Nycomed Gmbh | Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient |
DE10061135C1 (en) * | 2000-12-07 | 2002-11-07 | Byk Gulden Lomberg Chem Fab | Stable gel preparation for oral administration of acid-labile drug, especially proton pump inhibitor, comprises multiple drug units dispersed in gel base |
DE10061136C1 (en) * | 2000-12-07 | 2002-10-24 | Byk Gulden Lomberg Chem Fab | Stable, rapidly disintegrating tablets containing proton pump inhibitors, useful for treating elevated gastric secretion, comprising multiple drug units and auxiliaries including basic filler |
DE10061138C1 (en) * | 2000-12-07 | 2002-08-14 | Byk Gulden Lomberg Chem Fab | Pharmaceutical preparation in the form of a juice containing an acid-labile active ingredient |
ATE541564T1 (en) * | 2000-12-07 | 2012-02-15 | Nycomed Gmbh | QUICKLY DISRUPTING TABLET WITH AN ACID LABEL ACTIVE INGREDIENT |
DE10061137B4 (en) * | 2000-12-07 | 2016-10-06 | Takeda Gmbh | New pharmaceutical preparation |
SE0101379D0 (en) | 2001-04-18 | 2001-04-18 | Diabact Ab | Composition that inhibits gastric acid secretion |
CN1596101A (en) | 2001-09-28 | 2005-03-16 | 麦克内尔-Ppc股份有限公司 | Fondant composition contained dosage forms |
MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
CA2490142A1 (en) * | 2002-07-03 | 2004-01-15 | Abbott Laboratories | Liquid dosage forms of proton pump inhibitors |
DE10244129B4 (en) * | 2002-09-23 | 2006-04-20 | Iongate Biosciences Gmbh | H + -K + -ATPase assay |
SE0203065D0 (en) | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
ME00524B (en) | 2003-03-10 | 2011-10-10 | Astrazeneca Ab | Novel process for the preparation of roflumilast |
TW200503783A (en) * | 2003-04-11 | 2005-02-01 | Altana Pharma Ag | Oral pharmaceutical preparation for proton pump antagonists |
CA2601250C (en) | 2005-03-16 | 2014-10-28 | Nycomed Gmbh | Taste masked dosage form containing roflumilast |
US8673352B2 (en) | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2725924C3 (en) * | 1977-06-08 | 1980-11-06 | Hobeg Hochtemperaturreaktor-Brennelement Gmbh, 6450 Hanau | Process for the production of spherical particles from low-melting organic substances |
DE3524572A1 (en) * | 1985-07-10 | 1987-01-15 | Thomae Gmbh Dr K | SOLID PHARMACEUTICAL FORMS FOR PERORAL USE CONTAINING 9-DEOXO-11-DEOXY-9,11- (IMINO (2- (2-METHOXYETHOXY) ETHYLIDEN) -OXY) - (9S) -ERYTHROMYCIN AND METHOD FOR THE PRODUCTION THEREOF |
JP2681373B2 (en) * | 1988-07-18 | 1997-11-26 | 塩野義製薬株式会社 | Method for manufacturing sustained-release preparation |
-
1999
- 1999-06-07 DE DE19925710A patent/DE19925710C2/en not_active Expired - Fee Related
-
2000
- 2000-05-30 CO CO00040091A patent/CO5160296A1/en unknown
- 2000-05-30 MY MYPI20002403A patent/MY138975A/en unknown
- 2000-06-07 AR ARP000102825A patent/AR024310A1/en unknown
- 2000-06-07 TW TW089111052A patent/TWI255720B/en not_active IP Right Cessation
- 2000-06-07 PE PE2000000565A patent/PE20010303A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AR024310A1 (en) | 2002-09-25 |
DE19925710A1 (en) | 2000-12-14 |
TWI255720B (en) | 2006-06-01 |
PE20010303A1 (en) | 2001-03-09 |
CO5160296A1 (en) | 2002-05-30 |
DE19925710C2 (en) | 2002-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2376202A1 (en) | Novel preparation and administration form comprising an acid-labile active compound | |
MY138975A (en) | Novel preparation and administration form comprising an acid-labile active compound | |
IL101225A0 (en) | Bi-and tricyclic amino alcohol esters,their preparation and pharmaceutical compositions containing them | |
GB2062465B (en) | Topical preparation containing nitroglycerine and optionally other medicaments | |
IE940583L (en) | Topical antimicrobial pharmaceutical compositions | |
ATE427925T1 (en) | PHENOXYCARBONIC ACID COMPOUNDS AND COMPOSITIONS FOR ADMINISTRATION OF ACTIVE INGREDIENTS | |
MY111841A (en) | Injectable liposomal pharmaceutical preparations | |
GR890100467A (en) | Method for preparating intravenous pharmaceutical compositions | |
HUT57541A (en) | Fungicidal compositions comprising substituted acrylic acid esters as active ingredient and process for producing the active ingredients | |
EP0049422A2 (en) | Stable nonaqueous solution of tetracycline salt | |
AU2960497A (en) | Process for producing a paraffin-based object and such an object | |
GR3017411T3 (en) | Production process of microspheres. | |
ATE84045T1 (en) | INHIBITING SUBSTANCES ENKEPHALINASE-B THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITIONS. | |
MY143793A (en) | Non-tabletted, chewable, individually dosed administration forms | |
IL86395A (en) | Pharmaceutical compositions with improved bioavailability containing flunarizine and polyethoxylated castor oil | |
DE60027601D1 (en) | DRUG PREPARATION WITH CONTROLLED RELEASE CONTAINING TRAMADOL HYDROCHLORIDE | |
DE68913078D1 (en) | Carboxylic acid esters, processes for their preparation and insecticides containing them as active ingredients. | |
EP0793963A4 (en) | Percutaneously administrable preparation | |
HUT39752A (en) | Insecticide, acaricide, and nematocide compositions containing pyridyl-thiono-phosphoric acid esters as active ingredients and process for preparing the active ingredient | |
EP0239527A3 (en) | Composition adopted for use as a transdermal formulation | |
PE59499A1 (en) | PHARMACEUTICAL COMPOSITION OF CYCLOSPORINE | |
CA2017155A1 (en) | Method for transplantation of fertilized ova | |
EP1046337A3 (en) | Waterbased formulations having fungicidal activity |